Fourth Annual Clinical & Postdoctoral Fellowship Competition from NMD4C, MDC to Open Fall 2024

NMD4C together with Muscular Dystrophy Canada (MDC) are excited to announce that our annual Neuromuscular Fellowship Competition will open again this fall for a fourth year! Please mark the following dates in your calendar:

2025 Neuromuscular Fellowship Competition Deadlines:

  • Competition Opens: September 3, 2024
  • Competition Closes: October 15, 2024

 

This annual funding competition provides salary support for early-career scientists to conduct postdoctoral studies in a laboratory focused on research of NMDs, and early-career clinicians to participate in neuromuscular medicine and electromyography fellowship training programs. For more information on the scope and guidelines of this competition, please consult either the postdoctoral fellowship competition guidelines here or clinical fellowship competition guidelines here. We will provide more information closer to the competition launch!

2025 clinical and research fellowships competition from NMD4C and MDC.

Read next...

06 - 2026 Basic Research Summer School - EN

NMD4C Hosts 3rd Annual Basic Research Summer School at uOttawa!

From June 8 to 10, 2026, we hosted the 3rd annual NMD4C Basic Research Summer School at the University of Ottawa. The program supported 28 neuromuscular research trainees (graduate students and postdoctoral fellows) from across Canada and focused on developing practical skills, strengthening core knowledge in neuromuscular research, and providing opportunities to present and discuss their work. Through a combination of tutorials, lectures, hands-on workshops in cutting-edge wet lab techniques, flash talks, and both structured and informal networking, participants engaged with faculty, exchanged ideas, and built connections across institutions and career stages. 

New Publication from the NMD4C Clinical Trial Network Strengthens Trial Capacity in Canada

We are pleased to share a new publication from the NMD4C Clinical Trial Network led by Kerri Lynn Schellenberg, Homira Osman, Maria Masnata, Rhiannon Hicks, Corinne Kagan, Ana Stosic, Stacey Lintern, Erin Beattie, Drs. Hanns Lochmüller, Craig Campbell, and Jean K Mah. This work focuses on the implementation of a coordinated Canadian neuromuscular clinical trial network to enhance trial readiness, capacity, and access in rare disease research.

Canadian-Led Phase II Studies Advance Vamorolone Evidence in Duchenne Muscular Dystrophy

Canadian-Led Phase II Studies Advance Vamorolone Evidence in Duchenne Muscular Dystrophy

NMD4C investigators contributed to two phase II studies evaluating vamorolone in boys with Duchenne muscular dystrophy across early childhood and adolescence, demonstrating safety, favorable pharmacokinetics, and potential efficacy. Led by Dr. Jean Mah and conducted across Canadian clinical trial sites with national and industry collaborators, the findings supported Health Canada approval of vamorolone as the first treatment for DMD in Canada. Leaders from both the clinical and patient advocacy communities, including Defeat Duchenne Canada, highlighted the impact of collaboration among patients, families, clinicians, and researchers in advancing care and improving access to new therapies.